Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$2.35 USD
+0.06 (2.62%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.30 -0.05 (-2.13%) 5:16 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
TARA 2.35 +0.06(2.62%)
Will TARA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TARA
Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ASTS, CRBU and DOMO are among after hour movers
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
Buy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002